Signaling pathways leading to microglial activation, including mitogen-activated protein kinases (MAPKs), toll-like receptors (TLRs), janus kinase/signal transducer and transcription activator (JAK/STAT), nuclear factor kappa light chain enhancer of activated B cells (NF-κB), and phosphoinositide 3-kinases/AKT (PI3K/AKT), may contribute to the development of precise therapeutic strategies targeting Alzheimer’s disease [78]. This evidence concerns the gene AKT1 and Alzheimer disease.